Ken Griffin A Tyr Pharma Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.51 - $2.24 $23,103 - $34,272	15,300 Added 7650.0%	15,500 $28,000
Q2 2024 Aug 14, 2024	SELL	$0.0 - $2.07 $0 - $15,110	-7,300 Reduced 97.33%	200 $0
Q1 2024 May 15, 2024	BUY	$1.42 - $2.02 $9,656 - $13,736	6,800 Added 971.43%	7,500 $14,000
Q4 2023 Feb 14, 2024	SELL	$1.11 - $1.51 $7,881 - $10,721	-7,100 Reduced 91.03%	700 $0
Q3 2023 Nov 14, 2023	SELL	$1.55 - $2.23 $2,945 - $4,237	-1,900 Reduced 19.59%	7,800 $12,000
Q2 2023 Aug 14, 2023	BUY	$1.72 - $2.57 $5,332 - $7,966	3,100 Added 46.97%	9,700 $20,000
Q1 2023 May 15, 2023	BUY	$1.88 - $2.5 $6,956 - $9,250	3,700 Added 127.59%	6,600 $13,000
Q4 2022 Feb 14, 2023	SELL	$2.02 - $2.49 $32,118 - $39,591	-15,900 Reduced 84.57%	2,900 $6,000
Q3 2022 Nov 14, 2022	BUY	$2.79 - $4.15 $14,787 - $21,995	5,300 Added 39.26%	18,800 $56,000

37.1M

30.2K

3.1K

Ticker LIFE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,625,000
Market Cap $53.2M
Description
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.